{
  "url": "https://finance.yahoo.com/news/oncolytics-biotech-announces-voting-results-205500130.html?.tsrc=rss&_guc_consent_skip=1754946076",
  "authorsByline": "PR Newswire",
  "articleId": "987bd63cd1844e56849a2430283acb46",
  "source": {
    "domain": "finance.yahoo.com",
    "location": {
      "country": "us",
      "state": "CA",
      "county": "Santa Clara County",
      "city": "Sunnyvale",
      "coordinates": {
        "lat": 37.3688301,
        "lon": -122.036349
      }
    }
  },
  "imageUrl": "https://media.zenfs.com/en/prnewswire.com/caf9efe53f239ce497937f5fab3fe90d",
  "country": "us",
  "language": "en",
  "pubDate": "2025-08-11T20:55:00+00:00",
  "addDate": "2025-08-11T21:50:47.093858+00:00",
  "refreshDate": "2025-08-11T21:50:47.093860+00:00",
  "score": 1.0,
  "title": "Oncolytics Biotech\u00ae Announces Voting Results from the Annual General Meeting of Shareholders",
  "description": "Oncolytics Biotech\u00ae Inc. (Nasdaq: ONCY) (TSX: ONC) (\"Oncolytics\" or the \"Corporation\" or the \"Company\"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.",
  "content": "SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech\u00ae Inc. (Nasdaq: ONCY) (TSX: ONC) (\"Oncolytics\" or the \"Corporation\" or the \"Company\"), a clinical-stage immunotherapy company developing pelareorep, today announced the voting results from its Annual General Meeting (AGM) of Shareholders held on Friday, August 8, 2025. A total of 37.42% of the issued and outstanding common shares of the Corporation were represented either in person or by proxy at the meeting.\n\nOn a vote by ballot, the eight nominees proposed by the Corporation were elected as Directors of Oncolytics to serve until the Corporation's next Annual Meeting of Shareholders or until their successors are elected or appointed, with shares represented at the meeting voting in favor of individual nominees as follows:\n\nIn addition to the election of all nominees listed as directors in the management information circular, dated June 18, 2025, Oncolytics shareholders approved all other resolutions placed before the meeting. These included fixing the number of directors of the Corporation for the ensuing year at eight and appointing the auditors for the Corporation for the ensuing year.\n\nFor more details on the matters covered at the annual meeting, please refer to the Corporation's management information circular available on SEDAR at https://www.sedarplus.ca/home/. Final voting results on all matters voted on at the annual meeting will also be filed on SEDAR.\n\nOncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in multiple first-line pancreatic cancer studies, two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in anal and colorectal cancer. It induces anti-cancer immune responses by converting immunologically \"cold\" tumors \"hot\" through the activation of innate and adaptive immune responses.",
  "medium": "Article",
  "links": [
    "https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.html",
    "https://www.sedarplus.ca/home/"
  ],
  "labels": [
    {
      "name": "Press Release"
    }
  ],
  "claim": "",
  "verdict": "",
  "keywords": [
    {
      "name": "Voting Results",
      "weight": 0.091971844
    },
    {
      "name": "Final voting results",
      "weight": 0.09108517
    },
    {
      "name": "Corporation",
      "weight": 0.09089578
    },
    {
      "name": "Oncolytics shareholders",
      "weight": 0.084762976
    },
    {
      "name": "Oncolytics Biotech",
      "weight": 0.08336494
    },
    {
      "name": "anti-cancer immune responses",
      "weight": 0.08182145
    },
    {
      "name": "promising results",
      "weight": 0.07985419
    },
    {
      "name": "Oncolytics",
      "weight": 0.07619644
    },
    {
      "name": "metastatic breast cancer",
      "weight": 0.07302515
    },
    {
      "name": "individual nominees",
      "weight": 0.069435395
    }
  ],
  "topics": [
    {
      "name": "Voting"
    },
    {
      "name": "Biotech"
    }
  ],
  "categories": [
    {
      "name": "Tech"
    }
  ],
  "taxonomies": [
    {
      "name": "/News/Business News/Company News",
      "score": 0.9853515625
    },
    {
      "name": "/News/Business News/Financial Markets News",
      "score": 0.95263671875
    },
    {
      "name": "/Finance/Investing/Stocks & Bonds",
      "score": 0.93115234375
    },
    {
      "name": "/Business & Industrial/Pharmaceuticals & Biotech",
      "score": 0.90771484375
    }
  ],
  "sentiment": {
    "positive": 0.32148883,
    "negative": 0.045831185,
    "neutral": 0.63267994
  },
  "summary": "Oncolytics Biotech\u00ae Inc. has announced the voting results from its Annual General Meeting (AGM) of Shareholders. A total of 37.42% of the issued and outstanding common shares were represented at the meeting. The eight nominees proposed by the Corporation were elected as Directors of Oncolytic to serve until their successors are elected or appointed. Other resolutions approved include fixing the number of directors for the next year at eight and appointing the auditors for the future.",
  "shortSummary": "Oncolytics Biotech reported 37.42% of shareholders voted in favour of their candidate at its annual meeting, with eight elected directors representing the company.",
  "translation": "",
  "translatedTitle": "",
  "translatedDescription": "",
  "translatedSummary": "",
  "reprint": false,
  "reprintGroupId": "88391f1517a34f289d6139b98df11e4d",
  "places": [],
  "scraped_sources": [],
  "argos_summary": "Oncolytics Biotech Inc. held its Annual General Meeting on August 8, 2025, where 37.42% of shareholders participated. All eight proposed nominees were elected as Directors, and shareholders approved additional resolutions, including the number of directors and the appointment of auditors for the upcoming year. The company is focused on developing pelareorep, an immunotherapeutic agent showing promise in treating various cancers.",
  "argos_id": "62ZY3NP70"
}